• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Analyst initiated coverage on Septerna with a new price target

    11/19/24 7:39:27 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEPN alert in real time by email
    Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00
    Get the next $SEPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEPN

    DatePrice TargetRatingAnalyst
    6/23/2025$26.00Buy
    H.C. Wainwright
    2/18/2025$14.00Overweight → Equal Weight
    Wells Fargo
    11/19/2024$38.00Overweight
    Analyst
    11/19/2024Buy
    TD Cowen
    11/19/2024$43.00Overweight
    Wells Fargo
    11/19/2024$50.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SEPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Septerna with a new price target

      H.C. Wainwright initiated coverage of Septerna with a rating of Buy and set a new price target of $26.00

      6/23/25 8:09:11 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00

      2/18/25 8:55:10 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on Septerna with a new price target

      Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00

      11/19/24 7:39:27 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    SEC Filings

    See more
    • SEC Form 8-K filed by Septerna Inc.

      8-K - Septerna, Inc. (0001984086) (Filer)

      6/18/25 4:31:30 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.

      SCHEDULE 13G/A - Septerna, Inc. (0001984086) (Subject)

      6/10/25 10:55:12 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.

      SCHEDULE 13G/A - Septerna, Inc. (0001984086) (Subject)

      5/15/25 4:37:36 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ra Capital Management, L.P.

      4 - Septerna, Inc. (0001984086) (Issuer)

      6/20/25 6:46:21 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sharp Shalini

      4 - Septerna, Inc. (0001984086) (Issuer)

      6/20/25 6:44:30 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Tong Jeffrey K

      4 - Septerna, Inc. (0001984086) (Issuer)

      6/20/25 6:42:51 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Septerna to Present at Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:45 p.m. ET in New York. A live webcast of the presentation will be available here and in the investors section of the company's website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of

      5/29/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

      Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, in Third Quarter of 2025 Ended First Quarter 2025 with $398.2 Million in Cash, Cash Equivalents and Marketable Securities; Novo Nordisk Collaboration to Significantly Extend Prior Runway Guidance of Early 2028 SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pi

      5/15/25 4:01:00 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

      Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 financial results. "Our Native Comp

      3/27/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care